KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Income from Continuing Operations (2016 - 2026)

Pacific Biosciences Of California has reported Income from Continuing Operations over the past 16 years, most recently at 40371000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 1802.7% year-over-year to 40371000.0; the TTM value through Dec 2025 reached 546376000.0, down 76.34%, while the annual FY2025 figure was 546376000.0, 76.34% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 40371000.0 at Pacific Biosciences Of California, down from 38000000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 2371000.0 in Q4 2024 and troughed at 426075000.0 in Q1 2025.
  • A 5-year average of 85431578.95 and a median of 69833000.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 102.89% in 2024 and later plummeted 1802.7% in 2025.
  • Year by year, Income from Continuing Operations stood at 69329000.0 in 2021, then decreased by 21.72% to 84384000.0 in 2022, then grew by 2.8% to 82018000.0 in 2023, then skyrocketed by 102.89% to 2371000.0 in 2024, then plummeted by 1802.7% to 40371000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for PACB at 40371000.0 in Q4 2025, 38000000.0 in Q3 2025, and 41930000.0 in Q2 2025.